Skip to main content
Erschienen in: Inflammation 1/2010

01.02.2010

Beneficial Effects of TLR-2/6 Ligation in Pulmonary Bacterial Infection and Immunization with Pseudomonas aeruginosa

verfasst von: Tanja Kerber-Momot, Damaris Leemhuis, Anke Lührmann, Antje Munder, Burkhard Tümmler, Reinhard Pabst, Thomas Tschernig

Erschienen in: Inflammation | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Pseudomonas aeruginosa (P. aeruginosa) is the major pathogen in nosocomial and life-threatening infections of immunocompromised or critically ill patients. The macrophage-activating lipopeptide-2 (MALP-2) activates the immune system via Toll-like receptors (TLR) 2 and 6 and leads to an accumulation of immune cells in lungs of young adult (8–10 week old) rats after intratracheal application. This is characterized by a high increase of granulocyte numbers in the BAL 24 h after MALP-2 treatment. It was hypothesized that MALP-2 may have a positive effect on the clinical course of an experimental infection. Therefore, rats were treated with MALP-2 at different time points following an infection with P. aeruginosa. The effect of MALP-2 in combination with immunization with inactivated P. aeruginosa was also investigated. Rats (n = 10) were infected intratracheally (i.t.) with 1 × 108 CFU P. aeruginosa on day 0. They were treated on day −3, −1, 0 and +1 with 2.5 μg MALP-2 or the vehicle i.t. In additional experiments, rats were immunized on day −21 and −14 with 1 × 108 CFU of inactivated P. aeruginosa bacteria and 2.5 μg MALP-2 or vehicle with 1 × 108 CFU of inactivated bacteria and isopropanol. The clinical score, rectal temperature and weight of the rats were checked in both treatment and immunization experiments twice a day. On day 2 they were sacrificed, CFU were determined in the left lung, the right lung being used for histology. In the group treated with MALP-2 1 day prior to infection significant effects were seen: The rectal temperature was about 2°C higher in comparison to the controls at 6 h and also 1 day after infection. Both the symptoms of the infection and the weight loss were significantly reduced. In addition, the CFU and the inflammation in the lung tissue were significantly lower. These effects were not observed after treatment on day −3, 0 or +1. The MALP-2 enhanced immunization only resulted in a tendency to clinical improvement. In conclusion, local immunostimulation at the appropriate time can enhance the host defense against bacteria in the lung.
Literatur
1.
Zurück zum Zitat Arnold, H., D. Bumann, M. Felies, B. Gewecke, M. Sorensen, J. E. Gessner, J. Freihorst, B. U. von Specht, and U. Baumann. 2004. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa. Infect. Immun. 72: 6546–6553.CrossRefPubMed Arnold, H., D. Bumann, M. Felies, B. Gewecke, M. Sorensen, J. E. Gessner, J. Freihorst, B. U. von Specht, and U. Baumann. 2004. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa. Infect. Immun. 72: 6546–6553.CrossRefPubMed
2.
Zurück zum Zitat Borsutzky, S., V. Fiorelli, T. Ebensen, A. Tripiciano, F. Rharbaoui, A. Scoglio, C. Link, F. Nappi, M. Morr, S. Butto, A. Cafaro, P. F. Mühlradt, B. Ensoli, and C. A. Guzman. 2003. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur. J. Immunol. 33: 1548–1556.CrossRefPubMed Borsutzky, S., V. Fiorelli, T. Ebensen, A. Tripiciano, F. Rharbaoui, A. Scoglio, C. Link, F. Nappi, M. Morr, S. Butto, A. Cafaro, P. F. Mühlradt, B. Ensoli, and C. A. Guzman. 2003. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur. J. Immunol. 33: 1548–1556.CrossRefPubMed
3.
Zurück zum Zitat Deiters, U., and P. F. Mühlradt. 1999. Mycoplasmal lipopeptide MALP-2 induces the chemoattractant proteins macrophage inflammatory protein 1alpha (MIP-1alpha), monocyte chemoattractant protein 1, and MIP-2 and promotes leukocyte infiltration in mice. Infect. Immun. 67: 3390–3398.PubMed Deiters, U., and P. F. Mühlradt. 1999. Mycoplasmal lipopeptide MALP-2 induces the chemoattractant proteins macrophage inflammatory protein 1alpha (MIP-1alpha), monocyte chemoattractant protein 1, and MIP-2 and promotes leukocyte infiltration in mice. Infect. Immun. 67: 3390–3398.PubMed
4.
Zurück zum Zitat Gomez, M. I., and A. Prince. 2007. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr. Opin. Pharmacol. 7: 244–251.CrossRefPubMed Gomez, M. I., and A. Prince. 2007. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr. Opin. Pharmacol. 7: 244–251.CrossRefPubMed
5.
Zurück zum Zitat Kaufmann, A., P. F. Mühlradt, D. Gemsa, and H. Sprenger. 1999. Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2. Infect. Immun. 67: 6303–6308.PubMed Kaufmann, A., P. F. Mühlradt, D. Gemsa, and H. Sprenger. 1999. Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2. Infect. Immun. 67: 6303–6308.PubMed
6.
Zurück zum Zitat Kofteridis, D. P., J. A. Papadakis, D. Bouros, P. Nikolaides, G. Kioumis, S. Levidiotou, E. Maltezos, S. Kastanakis, S. Kartali, and A. Gikas. 2004. Nosocomial lower respiratory tract infections: prevalence and risk factors in 14 Greek hospitals. Eur. J. Clin. Microbiol. Infect. Dis. 23: 888–891.PubMed Kofteridis, D. P., J. A. Papadakis, D. Bouros, P. Nikolaides, G. Kioumis, S. Levidiotou, E. Maltezos, S. Kastanakis, S. Kartali, and A. Gikas. 2004. Nosocomial lower respiratory tract infections: prevalence and risk factors in 14 Greek hospitals. Eur. J. Clin. Microbiol. Infect. Dis. 23: 888–891.PubMed
7.
Zurück zum Zitat Lührmann, A., U. Deiters, J. Skokowa, M. Hanke, J. E. Gessner, P. F. Mühlradt, R. Pabst, and T. Tschernig. 2002. In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application. Infect. Immun. 70: 3785–3792.CrossRefPubMed Lührmann, A., U. Deiters, J. Skokowa, M. Hanke, J. E. Gessner, P. F. Mühlradt, R. Pabst, and T. Tschernig. 2002. In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application. Infect. Immun. 70: 3785–3792.CrossRefPubMed
8.
Zurück zum Zitat Lührmann, A., T. Tschernig, R. Pabst, and S. Niewiesk. 2005. Improved intranasal immunization with live-attenuated measles virus after co-inoculation of the lipopeptide MALP-2. Vaccine. 23: 4721–4726.CrossRefPubMed Lührmann, A., T. Tschernig, R. Pabst, and S. Niewiesk. 2005. Improved intranasal immunization with live-attenuated measles virus after co-inoculation of the lipopeptide MALP-2. Vaccine. 23: 4721–4726.CrossRefPubMed
9.
Zurück zum Zitat Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15: 194–222.CrossRefPubMed Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15: 194–222.CrossRefPubMed
10.
Zurück zum Zitat Mühlradt, P. F., M. Kiess, H. Meyer, R. Sussmuth, and G. Jung. 1997. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J. Exp. Med. 185: 1951–1958.CrossRefPubMed Mühlradt, P. F., M. Kiess, H. Meyer, R. Sussmuth, and G. Jung. 1997. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J. Exp. Med. 185: 1951–1958.CrossRefPubMed
11.
Zurück zum Zitat Pabst, R. 2008. Are animal models of asthma useful. In: Allergy and allergic diseases,2nd edition eds. A. B. Kay, A. P. Kaplan, J. Bousquet, and P. G. Holt, 1214–1222. Blackwell: Oxford. Pabst, R. 2008. Are animal models of asthma useful. In: Allergy and allergic diseases,2nd edition eds. A. B. Kay, A. P. Kaplan, J. Bousquet, and P. G. Holt, 1214–1222. Blackwell: Oxford.
12.
Zurück zum Zitat Reppe, K., T. Tschernig, A. Lührmann, V. van Laak V, K. Grote, M. V. Zemlin, B. Gutbier, H. C. Muller, M. Kursar, H. Schutte, S. Rosseau, R. Pabst, N. W. Suttorp, and M. Witzenrath. 2008. Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia. Am. J. Respir. Cell Mol. Biol. 40(4): 474–481. doi:10.1165/rcmb.2008-0071OC.CrossRefPubMed Reppe, K., T. Tschernig, A. Lührmann, V. van Laak V, K. Grote, M. V. Zemlin, B. Gutbier, H. C. Muller, M. Kursar, H. Schutte, S. Rosseau, R. Pabst, N. W. Suttorp, and M. Witzenrath. 2008. Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia. Am. J. Respir. Cell Mol. Biol. 40(4): 474–481. doi:10.​1165/​rcmb.​2008-0071OC.CrossRefPubMed
13.
Zurück zum Zitat Rharbaoui, F., B. Drabner, S. Borsutzky, U. Winckler, M. Morr, B. Ensoli, P. F. Mühlradt, and C. A. Guzman. 2002. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur. J. Immunol. 32: 2857–2865.CrossRefPubMed Rharbaoui, F., B. Drabner, S. Borsutzky, U. Winckler, M. Morr, B. Ensoli, P. F. Mühlradt, and C. A. Guzman. 2002. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur. J. Immunol. 32: 2857–2865.CrossRefPubMed
14.
Zurück zum Zitat Rharbaoui, F., A. Westendorf, C. Link, S. Felk, J. Buer, M. Gunzer, and C. A. Guzman. 2004. The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect. Immun. 72: 6978–6986.CrossRefPubMed Rharbaoui, F., A. Westendorf, C. Link, S. Felk, J. Buer, M. Gunzer, and C. A. Guzman. 2004. The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect. Immun. 72: 6978–6986.CrossRefPubMed
15.
Zurück zum Zitat Shingu, K., C. Kruschinski, A. Lührmann, K. Grote, T. Tschernig, S. von Hörsten, and R. Pabst. 2003. Intratracheal macrophage-activating lipopeptide-2 reduces metastasis in the rat lung. Am. J. Respir. Cell. Mol. Biol. 28: 316–321.CrossRefPubMed Shingu, K., C. Kruschinski, A. Lührmann, K. Grote, T. Tschernig, S. von Hörsten, and R. Pabst. 2003. Intratracheal macrophage-activating lipopeptide-2 reduces metastasis in the rat lung. Am. J. Respir. Cell. Mol. Biol. 28: 316–321.CrossRefPubMed
16.
Zurück zum Zitat Trautmann, M., P. M. Lepper, and M. Haller. 2005. Ecology of Pseudomonas aeruginosa in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. Am. J. Infect. Control. 33: S41–S49.CrossRefPubMed Trautmann, M., P. M. Lepper, and M. Haller. 2005. Ecology of Pseudomonas aeruginosa in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. Am. J. Infect. Control. 33: S41–S49.CrossRefPubMed
17.
Zurück zum Zitat Tschernig, T., A. Lührmann, and R. Pabst. 2002. Recruitment of lymphocytes and dendritic cells from the blood to the bronchoalveolar space and the draining lymph nodes after a single intrabronchial application of the lipopeptide MALP-2. Pathobiology. 70: 260–265.CrossRefPubMed Tschernig, T., A. Lührmann, and R. Pabst. 2002. Recruitment of lymphocytes and dendritic cells from the blood to the bronchoalveolar space and the draining lymph nodes after a single intrabronchial application of the lipopeptide MALP-2. Pathobiology. 70: 260–265.CrossRefPubMed
18.
Zurück zum Zitat Tschernig, T., D. Neumann, A. Pich, M. Dorsch, and R. Pabst. 2008. Experimental bronchial asthma - the strength of the species rat. Curr Drug Targets. 9: 466–469.CrossRefPubMed Tschernig, T., D. Neumann, A. Pich, M. Dorsch, and R. Pabst. 2008. Experimental bronchial asthma - the strength of the species rat. Curr Drug Targets. 9: 466–469.CrossRefPubMed
19.
Zurück zum Zitat Wiehlmann, L., A. Munder, T. Adams, M. Juhas, H. Kolmar, P. Salunkhe, and B. Tümmler. 2007. Functional genomics of Pseudomonas aeruginosa to identify habitat-specific determinants of pathogenicity. Int. J. Med. Microbiol. 297: 615–623.CrossRefPubMed Wiehlmann, L., A. Munder, T. Adams, M. Juhas, H. Kolmar, P. Salunkhe, and B. Tümmler. 2007. Functional genomics of Pseudomonas aeruginosa to identify habitat-specific determinants of pathogenicity. Int. J. Med. Microbiol. 297: 615–623.CrossRefPubMed
Metadaten
Titel
Beneficial Effects of TLR-2/6 Ligation in Pulmonary Bacterial Infection and Immunization with Pseudomonas aeruginosa
verfasst von
Tanja Kerber-Momot
Damaris Leemhuis
Anke Lührmann
Antje Munder
Burkhard Tümmler
Reinhard Pabst
Thomas Tschernig
Publikationsdatum
01.02.2010
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 1/2010
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-009-9158-7

Weitere Artikel der Ausgabe 1/2010

Inflammation 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.